GleamWall
中文EN

PFSA Profusa, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1859807 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY23.0%
TTM EPS YoY197.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-155.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.0%
Debt / equity0.00x
Current ratio0.02x
Interest coverage-174.12x

Cash quality & payout

Operating cash flow / net income0.47x
Accruals ratio-82.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$100,000
R&D expense$2.80M$1.61M
SG&A expense$24.90M$2.99M
Operating income-$27.71M-$4.50M
Interest expense$2.52M$4.42M
Pretax income—-$8.63M
Income tax—$80,513
Net income-$35.82M-$9.23M
EPS (basic)-107.01-357.14
EPS (diluted)-107.01-357.14
Weighted avg. shares (diluted)334,76225,844
Balance sheet
Cash & equivalents$1.78M$191,000
Current assets$3.76M$260,000
PP&E, net$8,000—
Total assets$3.77M$3.07M
Current liabilities$22.26M$57.13M
Total liabilities$30.43M$57.13M
Shareholders' equity-$26.66M-$119.20M
Shares outstanding12,32025,844
Cash flow statement
Operating cash flow-$16.25M-$2.07M
Capital expenditure$8,000—
Free cash flow-$16.26M—
Investing cash flow-$2.01M$2.97M
Financing cash flow$19.84M$2.12M
Stock-based compensation$891,000$21,000
Share buybacks—$3.25M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.